Untargeted Discovery of Metabolic Compensation for Antifolate Therapies in Triple-negative Breast Cancer: A Multi'Omic Strategy to Reveal Targetable Synthetic Lethalities

Triple-negative breast cancer (TNBC) has been incurable to date, with individuals invariably suffering from relapses and death, despite standard-of-care treatments. Metabolic reprograming is now recognized as a fundamental driver of cancer and a detailed understanding of metabolic rewiring that occurs in TNBC will undoubtedly reveal novel therapeutic opportunities. The overarching goal of the research presented will be to describe a multi’Omic strategy for broad discovery of metabolomic responses to antifolate cancer chemotherapy in TNBC that may oppose therapeutic benefit, and uncover novel approaches for targeted/personalized combination therapies that may improve outcomes.

For Research Use Only. Not for use in diagnostic procedures.